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Lack of TAR-DNA binding protein-43 (TDP-43) pathology in human prion diseases
Aims:TAR-DNAbindingprotein-43(TDP-43)isthemajor
ubiquitinated protein in the aggregates in frontotemporal
dementia with ubiquitin-positive, tau-negative inclusions
and motor neurone disease. Abnormal TDP-43 immu-
noreactivity has also been described in Alzheimer’s
disease, Lewy body diseases and Guam parkinsonism–
dementia complex. We therefore aimed to determine
whether there is TDP-43 pathology in human prion dis-
eases, which are characterised by variable deposition of
prion protein (PrP) aggregates in the brain as amyloid
plaques or more diffuse deposits. Material and methods:
TDP-43, ubiquitin and PrP were analysed by immunohis-
tochemistryanddouble-labellingimmunoﬂuorescence,in
sporadic, acquired and inherited forms of human prion
disease. Results: Most PrP plaques contained ubiquitin,
whilesynapticPrPdepositswerenotassociatedwithubiq-
uitin. No abnormal TDP-43 inclusions were identiﬁed
in any type of prion disease case, and TDP-43 did not
co-localize with ubiquitin-positive PrP plaques or with
diffuse PrP aggregates. Conclusions: These data do not
support a role for TDP-43 in prion disease pathogenesis
and argue that TDP-43 inclusions deﬁne a distinct group
of neurodegenerative disorders.
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Introduction
TAR-DNA binding protein-43 (TDP-43) has recently been
identiﬁed as the major protein in the ubiquitinated inclu-
sions that characterize frontotemporal lobar degenera-
tion with ubiquitin-positive, tau-negative inclusions
(FTLD-U) and motor neurone disease (MND) [1]. TDP-43
pathology has since been reported in ubiquitinated in-
clusions in Alzheimer’s disease cases [2,3], in Guam
parkinsonism–dementia complex brains [4,5] and in
Lewy body-related diseases [3,6]. Occasional TDP-43
staining has also been noted in neuroﬁbrillary tangles
[2,3,7] and in corticobasal degeneration [7] and Pick’s
disease brains [7,8]. These ﬁndings show that a number
of neurodegenerative diseases characterized by protein
aggregation have pathologicalTDP-43 immunoreactivity,
prompting us to look in prion disease brains, which also
contain protein aggregates.
Human prion diseases are a clinically and neuropatho-
logically diverse group of neurodegenerative disorders in
which conversion of host-encoded prion protein, termed
PrP
C, to an abnormally folded and aggregated form,
termed PrP
Sc, is a central feature [9,10].
Approximately 85% of human prion diseases occur
as sporadic Creutzfeldt–Jakob disease (CJD) [11], and
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causedbymutationsintheprionproteingene(PRNP)[9].
Susceptibility to sporadic prion diseases, as well as the
acquired prion diseases described below, is affected by the
genotype at codon 129 of PRNP [12–17]. Traditionally,
the inherited cases have been classiﬁed as Gerstmann–
Sträussler–Scheinkerdisease(GSS),fatalfamilialinsomnia
(FFI) or CJD; however, the range of clinical presentations,
even within families with the same PRNP mutation
[18–22], has led to sub-classiﬁcation based on the PRNP
mutation and the genotype at codon 129 [20,23].
Acquiredpriondiseasesareararecauseof priondisease
in most populations, but can have a high frequency in
certain populations. Acquired prion diseases can be clas-
siﬁed as kuru, iatrogenic CJD or variant CJD (vCJD). Iatro-
genicCJDhasbeencausedbyprionexposurefrommedical
and surgical procedures, such as dura mater grafts,
human growth hormone treatment and contamination of
surgical equipment [24,25]. vCJD was ﬁrst identiﬁed in
the UK in 1995 as a novel variant of CJD [26], and gener-
ally has a much earlier age of onset than sporadic CJD
[27]. The prion strain identiﬁed in vCJD has the same
characteristics as bovine spongiform encephalopathy
(BSE) prions, suggesting that dietary exposure to BSE-
infected cattle was the cause for the vCJD outbreak
[28–31].There is now strong evidence that vCJD can also
be transmitted by blood transfusion [32–34].
There are several characteristic neuropathological
changes in the prion diseases described above: neuronal
loss, astrocytic gliosis and spongiform vacuolation [35].
The latter can be absent in FFI [36] and can also be absent
in severely ‘burnt-out’ areas, in which few neurons
remain. Abnormal accumulation of PrP is generally
observed, but the extent and form are variable [35] and,
likespongiosis,isoccasionallynotobservedinFFI[35,36].
GSS and kuru are characterized by PrP-positive amyloid
plaques [35,37], while in sporadic CJD diffuse synaptic
accumulationof PrP,whichcanalsobeseeninGSS,ismore
common[35,37].vCJDischaracterizedbyabundantﬂorid
amyloidplaques,inwhichthesurroundingtissueismicro-
vacuolated[26,38],butdiffusedepositscanbeseenaswell.
Ubiquitin immunohistochemistry (IHC) in sporadic CJD
and GSS has previously revealed staining at the periphery
of amyloid plaques and around areas of spongiform
change[39].BecauseTDP-43pathologycanbeassociated
with ubiquitinated deposits, and has now been observed
in a number of neurodegenerative diseases, we analysed
ubiquitin, PrP and TDP-43 immunoreactivity in different
forms of prion diseases, including sporadic, inherited and
acquired cases. PrP plaques were often accompanied by
punctate ubiquitin deposits, but both PrP and ubiquitin
staining were not associated with any TDP-43 cytoplas-
micaccumulation,suggestingthatTDP-43isprobablynot
involved in prion disease pathogenesis.
Materials and methods
Use of human tissues
Human tissues were obtained at autopsy with consent for
use in research.This study was approved by the UCL Insti-
tute of Neurology and National Hospital for Neurology
and Neurosurgery Local Research Ethics Committee.
Antibodies
Anti-TDP-43 (ProteinTech Group, Chicago, IL, USA),
1:10 000 for IHC, 1:150 for immunoﬂuorescence (IF).
Anti-ubiquitin (SC-8017, Santa Cruz Biotechnology,
SantaCruz,CA,USA)1:5000forIHC,1:2500forIF.Anti-
PrP ICSM35 (D-Gen, London, UK) was raised in Prnp
o/o
mice against recombinant b-PrP as previously described
[40] and was used at 1:1000 for IHC and 1:500 for IF.
Immunohistochemistry
Formalin-ﬁxed brain samples were immersed in 98%
formic acid for 1 h to denature infectious prions. Brain
samples were then processed and 10-mm parafﬁn sections
were cut and allowed to dry overnight at room tempera-
ture,thenbakedfor2 hat60°C.Sectionswerepre-treated
by boiling in 1 M citrate buffer pH 6.0 (TDP-43 and
ubiquitin antibodies) and tris-EDTA-citrate buffer pH 7.8
(ICSM35). For speciﬁc detection of aggregated disease-
associated PrP with ICSM35, sections were immersed in
98% formic acid for 5 min and treated with proteases to
abolish the PrP
C signal. IHC was carried out on an auto-
mated immunostaining machine (Benchmark, Ventana
Medical Systems Inc.,Tucson, AZ, USA) using proprietary
protease and secondary detection reagents and developed
with 3′3 diaminobenzedine tetrachloride as the chro-
mogen. Sections were counterstained with haematoxylin.
Bright ﬁeld photographs were taken on an ImageView
II 3.5 Mpix digital camera (Soft Imaging Solutions
GmbH, Münster, Germany, http://www.soft-imaging.de)
mounted on a ZEISS Axioplan microscope (Carl Zeiss Jena
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Double-labelling IF
Sections were pre-treated by pressure cooking for 20 min
in1 McitratebufferpH 6.0(ubiquitinandTDP-43double
labelling); 20-min pressure cooking in 1 M citrate buffer
pH 6.0 followed by protease treatment (ubiquitin and
ICSM35 double labelling); or pressure cooking for 20 min
in 1 M citrate buffer pH 6.0 followed by 98% formic acid
for 5 min and then protease treatment (TDP-43 and
ICSM35doublelabelling).Sectionsweremanuallystained
sequentially for each primary antibody followed by detec-
tion with the relevant secondary antibodies; Alexa Fluor
anti-rabbit 488; Alexa Fluor anti-mouse 546, Alexa Fluor
anti-IgG1 488; Alexa Fluor anti-IgG2b 546 (all from
Invitrogen, Carlsbad, CA, USA and used at 1:400). Laser
scanning confocal microscopy was performed with a Zeiss
LSM510 META, mounted on Zeiss Axiovert 200 M. All
images were recorded using a ZEISS Plan-Apochromat
20x/0.75 objective. Image analysis was performed using
Zeiss LSM software.
Results
PrP plaques but not diffuse PrP aggregates
contain ubiquitin deposits
We initially examined PrP and ubiquitin immunoreactiv-
ity in the frontal cortex of a variety of inherited prion
disease cases as well as sporadic, iatrogenic and variant
CJD samples. In addition, we also analysed the cerebellum
of a case with diagnosed GSS carrying a P102L mutation.
Details of the cases examined are given in Table 1.
Disease-associated PrP was detected with the mono-
clonal antibody ICSM35 as described in the methods. We
scored the abundance of PrP plaques and diffuse PrP
aggregates for each case in a semi-quantitative assess-
ment, and analysed ubiquitin pathology in these scored
cases. As expected, vCJD brains contained abundant PrP-
positive plaques (Figure 1A,D), as did one inherited prion
disease case with a six-octapeptide-repeat insertion
(6OPRI) in PRNP (Figure 2J). Interestingly, another case
with the same 6OPRI insertion mutation had no PrP
plaques, but rather ﬁne axonal and dendritic PrP staining
in grey and white matter, conﬁrming the neuropathologi-
cal heterogeneity even of cases with the same mutation
(data not shown). The P102L (GSS) brain contained
mature PrP plaques (Figure 2G), while the D178N (FFI)
case had more diffuse or primitive plaques (but no core
plaques) (Figure 2M). PrP plaques were consistently
dotted with small ubiquitin aggregates, except in the
D178N (FFI) case in which the correlation between the
diffuse plaques and ubiquitin deposits was less obvious
(Figure 2N). The plaques could be clearly identiﬁed by
ubiquitin immunoreactivity using both standard IHC and
IF (Figure 3). Double labelling conﬁrmed the presence of
small ubiquitin deposits within PrP plaques (Figure 3),
and also showed that some D178N (FFI) plaques con-
tained ubiquitin deposits (Figure 3F).
Diffuse synaptic PrP aggregates were observed in the
sporadic CJD cases as well as in other cases, but did not
show any apparent co-localization with ubiquitin
(Table 1, Figures 1 and 2). The lack of co-localization
between diffuse PrP aggregates and ubiquitin was
conﬁrmed by double-labelling IF (Figure 3). These data
suggest that PrP plaques, but not diffuse PrP pathology,
contain ubiquitin deposits.
PrP and ubiquitin aggregates in human prion
diseases are TDP-43-negative
The TDP-43 immunoreactivity was initially analysed
in the frontal cortex of all of the prion disease cases
described. TDP-43 was nuclear in all cases, and did not
appear to co-localize with diffuse PrP, PrP plaques or
plaque-associated ubiquitin deposits in any of the cases
(Figures 1and2).Noco-localizationof TDP-43withubiq-
uitin, or TDP-43 with PrP aggregates was seen using
double-labelling IF (Figure 3).
AbnormalTDP-43accumulationhasalsobeenreported
in the hippocampus in Alzheimer’s disease and dementia
with Lewy bodies [3].Therefore, we also analysedTDP-43
immunoreactivity in the hippocampus in all cases, and
similarlytofrontalcortexfoundnoabnormalities(datanot
shown). TDP-43 pathology has been reported in the
absence of ubiquitin immunoreactivity in both white
and grey matter of FTLD-U cases [42–44] and Guam
parkinsonism–dementia complex cases [5]. We examined
TDP-43 in the white matter and in grey matter areas not
associated with PrP pathology in both hippocampus and
frontal cortex, but did not observe any abnormal TDP-43
staining. Re-localization of TDP-43 from the nucleus to
cytoplasmic aggregates appears to be a characteristic
ﬁnding in TDP-43 proteinopathies, but reduced nuclear
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activity, rather than distinct inclusions, has also been
reported [42,43,45]. We therefore also examined the
frontal cortex and hippocampus of prion disease cases for
instances of cytoplasmic rather than nuclear TDP-43
localization, but did not observe any such staining.
One possible confounding factor is that all formalin-
ﬁxed prion disease brains were immersed in formic acid
prior to processing to abolish prion infectivity. To exclude
the possibility that formic acid treatment alters pathologi-
calTDP-43immunoreactivity(normalnuclearstainingof
TDP-43 was very strong in formic acid-treated brains), we
analysed two progranulin-positive FTLD-U cases [46]. For
each FTLD-U case, two samples of frontal cortex were
processed separately, either with or without formic acid
treatment. Immunostaining revealed extensive TDP-43
pathology in both the formic acid-treated and untreated
samples(Figure 1J,K),conﬁrmingthatthelackof TDP-43
pathology in our prion disease brains was not due to
formic acid treatment. These data therefore show that
TDP-43pathologyisnotobservedinawiderangeof prion
brains with differing PrP pathology.
Figure 1. Prion protein (PrP), ubiquitin and TAR-DNA binding protein-43 (TDP-43) staining in acquired prion diseases: In all cases, prion
protein plaques co-localize with ubiquitin aggregates, but no TDP-43 abnormalities are observed. (A–C) Variant Creutzfeldt–Jakob disease
(vCJD) with characteristic dense PrP deposits surrounded by vacuolations (‘ﬂorid plaques’). Even in close proximity to the plaques, there is
no abnormal nuclear deposition of TDP-43. (D–F) Abundant plaques in another vCJD case, again co-localizing with ubiquitin granular
deposits. (G–I) Synaptic and plaque deposits in iatrogenic CJD, which contain ubiquitin but not TDP-43. Progranulin-positive frontotemporal
lobar degeneration with ubiquitin-positive, tau-negative inclusions (FTLD-U) case showing neuritic pathology in the absence (J), or presence
(K) of formic acid treatment. An intranuclear inclusion is also apparent in the formic acid-treated sample. Numbers indicate case numbers
(see Table 1). Scale bar: 50 mm for images A–F, 100 mm for images G and H and 36 mm for J and K.
450 A. M. Isaacs et al.
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TDP-43 was initially shown to be the major ubiquitinated
protein in the inclusions in FTLD-U and MND [1]. Subse-
quently, TDP-43 pathology was identiﬁed in Alzheimer’s
disease, Guam parkinsonism–dementia complex and
Lewy body diseases [2–6]. It is therefore important to
deﬁne the range of neurodegenerative diseases with
protein aggregates that harbour TDP-43 pathology.
Prion disease brains usually contain PrP aggregates,
and a previous study showed ubiquitin staining in the
periphery of plaques in GSS and sporadic cases, as well
as ubiquitin immunoreactivity around areas of spongi-
form change [39]. We have now extended the analysis of
ubiquitin in prion disease brains by examining a wide
range of human prion disease cases including variant
CJD and a variety of inherited cases with distinct patho-
logical features. We did not observe ubiquitin in areas of
Figure 2. Prion protein (PrP), ubiquitin and TAR-DNA binding protein-43 (TDP-43) staining in sporadic and inherited prion diseases. (A–C)
sCJD with synaptic PrP deposition, very little punctate ubiquitin deposits and normal TDP-43 labelling. (D,G,J,M) Inherited prion diseases
with various types of prion protein deposits. (D–F) A117V mutation with diffuse, synaptic deposits, again with no marked ubiquitin
deposition and no TDP-43 abnormalities. (G–I) GSS with P102L mutation shows marked ubiquitin aggregates in and around plaques. (J–L)
Case of six-octapeptide-repeat insertion (144-bp insert) with abundant, dense prion protein deposits, mainly presenting with ‘primitive’
plaques (J), which are accompanied by ubiquitin aggregates (K), but no changes in TDP-43. (M–O) FFI with diffuse PrP plaques (M), no
ubiquitin and no TDP-43 abnormalities. Numbers below the disease type indicate case numbers (see Table 1). Scale bar 100 mm for all
images except C, I, F, L and O for which the scale bar is 50 mm.
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© 2008 Blackwell Publishing Ltd, Neuropathology and Applied Neurobiology, 34, 446–456spongiform change, as was previously described, which
may be due to differences in antibody speciﬁcity or sen-
sitivity, or the particular staining and pre-treatment
protocols used. We show here that PrP plaques, but
not diffuse (synaptic) PrP aggregates, contain ubiquitin
deposits. Interestingly, the more diffuse PrP plaques in
FFI stained less often for ubiquitin than more compact
PrP plaques, possibly indicating that compaction of
plaques facilitates their ubiquitination or that ubiquitin
is sequestered into compact plaques.
We examined a number of different cases of prion
disease with ubiquitin-positive PrP plaques. Ubiquitin
deposits were always negative for TDP-43, and TDP-43
did not show abnormal cytoplasmic aggregation nearby
or distant from plaques. TDP-43 was also normal in
areas with diffuse PrP aggregates and in areas without
any abnormal PrP immunoreactivity, including the
white matter. These data suggest that TDP-43 is probably
not involved in the pathogenesis or progression of prion
diseases. TDP-43 pathology, therefore, appears to be spe-
ciﬁc to a subset of neurodegenerative diseases, which
may share some aetiological features. Understanding the
role and signiﬁcance of TDP-43 in these cases is now a
fundamental question in the ﬁeld, and helping to deﬁne
the clinical spectrum of TDP-43 proteinopathies, as we
have done here, is an important ﬁrst step in this process.
Prion diseases and TDP-43 proteinopathies share the
feature of protein aggregation, and there is some evi-
dence that PRNP may have a role in Alzheimer’s disease
[47–49]. There is also conﬂicting data on whether PRNP
genotype can affect the risk of FTD [50–52]. However,
the lack of TDP-43 pathology in prion diseases suggests
that if there is a common pathogenic pathway with
TDP-43 proteinopathies, it is downstream of TDP-43.
This could also be the case with certain disorders that
are in the clinical and neuropathological spectrum of
TDP-43 proteinopathies but which are TDP-43-negative,
such as SOD1-positive MND [53,54] and certain FTLD-U
cases [42,55].
Inconclusion,humanpriondiseasesdonothavedetect-
able TDP-43 pathology, further deﬁning the spectrum of
TDP-43 proteinopathies.
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